SynthesisFrontiers in cardiovascular medicine2022
Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer.
Synthesis in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06881940 (Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Rationale and Design of a Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With Anthracyclines and/or Trastuzumab: A Randomized, Active Control Group, Open-Label Trial
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A meta-analysis on the impact of concurrent or pre-existing cancer diagnosis on acute myocardial infarction outcomes.PloS one · 2025Pooled it
- Cardiovascular disease incidence and cancer risk in two large European prospective cohorts.International journal of cancer · 2026Article
- Risk factors associated with cardiovascular hospital admissions and all-cause mortality in cancer patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Review
- Socioeconomic and Engagement Barriers to Cardiovascular Risk Awareness Among Cancer Survivors.Research square · 2026Article
- Cardio-oncology in multidisciplinary synergy: addressing the rising burden of cancer therapy-related cardiovascular toxicity (CTR-CVT) in advancing oncology practices.Oncology reviews · 2026Review
- The emerging role of echocardiography-based techniques in cardio-onco-hematology.Frontiers in oncology · 2026Review
- Cancer-driven cytokine immunomodulation ameliorates cardiac function and suppresses fibrosis.Journal of molecular and cellular cardiology plus · 2025Article
- Cardiovascular Disease Meets Cancer: Exploring the Epidemiology in China and Homotherapy Targeting Intersectional Mechanisms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database.BMC cancer · 2025Article
- Core outcome set for cardio-oncology: development of a set of outcomes for the cardiovascular assessment and monitoring of cancer patients and survivors.European heart journal. Quality of care & clinical outcomes · 2025Article
- Survivin in cardiovascular diseases and its therapeutic potential.Vascular pharmacology · 2025Review
- AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- The interplay between cancer and cardiovascular disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Out-of-hospital cardiac arrest event after cancer diagnosis: a korean metropolitan cohort study.BMC cancer · 2025Article
- Association Between Advanced TNM Stages and Increased Risk of Cardiac Dysfunction in Patients with LVEF < 50.Medicina (Kaunas, Lithuania) · 2025Article
- Nutritional health aspects and functional properties of nut yogurt: Future perspectives.Food chemistry: X · 2025Review
- Mitochondrial micro RNAs: Crucial players in carcinogenesis.Oncology research · 2025Review
- Green synthesis and characterization of iron nanoparticles synthesized from bioflocculant for wastewater treatment: A review.Biotechnology notes (Amsterdam, Netherlands) · 2025Review
- Cardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health.Cancers · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) and cancer are the leading causes of death worldwide. With an increasing number of the elderly population, and early cancer screening and treatment, the number of cancers cases are rising, while the mortality rate is decreasing. However, the number of cancer survivors is increasing yearly. With the prolonged life span of cancer patients, the adverse effects of anti-tumor therapy, especially CVD, have gained enormous attention. The incidence of cardiovascular events such as cardiac injury or cardiovascular toxicity is higher than malignant tumors' recurrence rate. Numerous clinical studies have also shifted their focus from the study of a single disease to the interdisciplinary study of oncology and cardiology. Previous studies have confirmed that anti-tumor therapy can cause CVD. Additionally, the treatment of CVD is also related to the tumors incidence. It is well established that the increased incidence of CVD in cancer patients is probably due to an unmodified unhealthy lifestyle among cancer survivors or cardiotoxicity caused by anti-cancer therapy. Nevertheless, some patients with CVD have a relatively increased cancer risk because CVD and malignant tumors are highly overlapping risk factors, including gender, age, hypertension, diabetes, hyperlipidemia, inflammation, and obesity. With advancements in the diagnosis and treatment, many patients simultaneously suffer from CVD and cancer, and most of them have a poor prognosis. Therefore, clinicians should understand the relationship between CVD and tumors, effectively identify the primary and secondary prevention for these diseases, and follow proper treatment methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.